Efficacy of Benralizumab and Clinical Course of IgG4 in Eosinophilic Granulomatosis With Polyangiitis

J Investig Allergol Clin Immunol. 2021 Jul 26;31(4):346-348. doi: 10.18176/jiaci.0648. Epub 2020 Oct 8.

Authors

Y Miyata¹, H Inoue¹, T Homma¹, A Tanaka¹, H Sagara¹

Affiliation

¹ Department of Internal Medicine, Division of Respiratory Medicine and Allergology, Showa University School of Medicine, Tokyo, Japan.

PMID: 33030432
DOI: 10.18176/jiaci.0648

No abstract available

Keywords: Anti-IL-5 receptor antibody; Benralizumab; Eosinophilic granulomatosis with polyangiitis (EGPA); IgG4; MPO-ANCA.

Publication types

Case Reports

MeSH terms

Adult
Anti-Asthmatic Agents / therapeutic use*
Antibodies, Monoclonal, Humanized / therapeutic use*
Eosinophilia / drug therapy*
Eosinophils / immunology*
Granulomatosis with Polyangiitis / drug therapy*
Humans
Immunoglobulin G / metabolism*
Interleukin-5 Receptor alpha Subunit / immunology
Male

Substances

Anti-Asthmatic Agents
Antibodies, Monoclonal, Humanized
IL5RA protein, human
Immunoglobulin G
Interleukin-5 Receptor alpha Subunit
benralizumab